Skip to main content

Recent Advances in the Studies of Molecular Mechanisms Regulating Multidrug Resistance in Cancer Cells

Biochemistry (Moscow) volume 83, pages 779–786 (2018)Cite this article

Abstract

Abstract—Here we present new approaches to better understanding multidrug resistance (MDR) development in cancer cells, such as identification of components of a complex process of MDR evolution. Recent advances in the studies of MDR are discussed: 1) chemotherapy agents might be involved in the selection of cancer stem cells resulting in the elevated drug resistance and enhanced tumorigenicity; 2) cell–cell interactions have a great effect on the MDR emergence and evolution; 3) mechanotransduction is an important signaling mechanism in cell–cell interactions; 4) proteins of the ABC transporter family which are often involved in MDR might be transferred between cells via microvesicles (epigenetic MDR regulation); 5) proteins providing cell-to-cell transfer of functional P-glycoprotein (MDR1 protein) via microvesicles have been investigated; 6) P-glycoprotein may serve to regulate apoptosis, as well as transcription and translation of target genes/proteins. Although proving once again that MDR is a complex multi-faceted process, these data open new approaches to overcoming it.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Abbreviations

ABC:

ATP binding cassette

CAFs:

cancer-associated fibroblasts

CSCs:

cancer stem cells

DR:

drug resistance

E-cad:

E-cadherin

ECM:

extracellular matrix

ES:

Ewing sarcoma

MDR:

multidrug resistance

MDR1 :

multidrug resistance gene 1, encodes Pgp

MVs:

microvesicles

NFs:

normal fibroblasts

Pgp:

P-glycoprotein (according to the current ABCB1 classification)

TNF:

tumor necrosis factor

TRAIL:

TNF-related apoptosis-inducing ligand

References

  1. Gottesman, M. M. (2002) Mechanisms of cancer drug resistance, Annu. Rev. Med., 53, 615–627.

    Article  PubMed  CAS  Google Scholar 

  2. Gottesman, M. M., Lavi, O., Hall, M. D., and Gillet, J.–P. (2016) Toward a better understanding of the complexity of cancer drug resistance, Annu. Rev. Pharmacol. Toxicol., 56, 85–102.

    Article  PubMed  CAS  Google Scholar 

  3. Gay, L., Baker, A.–M., and Graham, T. A. (2016) Tumour cell heterogeneity, F1000Research, 5, 238.

    Article  Google Scholar 

  4. Wind, N. S., and Holen, I. (2011) Multidrug resistance in breast cancer: from in vitro models to clinical studies, Int. J. Breast Cancer, 2011, 967419.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Coley, H. M. (2010) Overcoming multidrug resistance in cancer: clinical studies of P–glycoprotein inhibitors, Methods Mol. Biol., 596, 341–358.

    Article  PubMed  CAS  Google Scholar 

  6. Thompson, P. A., Kantarjian, H. M., and Cortes, J. E. (2015) Diagnosis and treatment of chronic myeloid leukemia in 2015, Mayo Clin. Proc., 90, 1440–1454.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Higgins, C. F. (2007) Multiple molecular mechanisms for multidrug resistance transporters, Nature, 446, 749–757.

    Article  PubMed  CAS  Google Scholar 

  8. Zhao, Y., Butler, E. B., and Tan, M. (2013) Targeting cel–lular metabolism to improve cancer therapeutics, Cell Death Dis., 4, e532.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Stavrovskaya, A. A., Stromskaya, T. P., Rybalkina, E. Y., Moiseeva, N. I., Guryanov, S. G., Ovchinnikov, L. P., and Guens, G. P. (2012) YB–1 protein and multidrug resistance of tumor cells, Curr. Signal Transduct. Ther., 7, 237–246.

    Article  CAS  Google Scholar 

  10. Flach, E. H., Rebecca, V. W., Herlyn, M., Smalley, K. S. M., and Anderson, A. R. A. (2011) Fibroblasts contribute to melanoma tumor growth and drug resistance, Mol. Pharm., 8, 2039–2049.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Sun, Y., Campisi, J., Higano, C., Beer, T. M., Porter, P., Coleman, I., True, L., and Nelson, P. S. (2012) Treatment–induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B, Nat. Med., 18, 1359–1368.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Oesper, L., Satas, G., and Raphael, B. J. (2014) Quantifying tumor heterogeneity in whole–genome and whole–exome sequencing data, Bioinformatics, 30, 3532–3540.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Esparza–Lopez, J., Escobar–Arriaga, E., Soto–Germes, S., and Ibarra–Sanchez, M. J. (2017) Breast cancer intra–tumor heterogeneity: one tumor, different entities, Rev. Invest. Clin., 69, 66–76.

    PubMed  Google Scholar 

  14. Hanahan, D., and Weinberg, R. A. (2011) Hallmarks of cancer: the next generation, Cell, 4, 646–674.

    Article  CAS  Google Scholar 

  15. Audia, A., Conroy, S., Glass, R., and Bhat, K. P. L. (2017) The impact of the tumor microenvironment on the proper–ties of glioma stem–like cells, Front. Oncol., 7, 143.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Bhowmick, N. A., and Moses, H. L. (2005) Tumor–stroma interactions, Curr. Opin. Genet. Dev., 15, 97–101.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Itoh, G., Chida, S., Yanagihara, K., Yashiro, M., Aiba, N., and Tanaka, M. (2017) Cancer–associated fibroblasts induce cancer cell apoptosis that regulates invasion mode of tumours, Oncogene, 36, 4434–4444.

    Article  PubMed  CAS  Google Scholar 

  18. Luria, S. E., and Delbuck, M. (1943) Mutations of bacteria from virus ensitivity to virus resistance, Genetics, 28, 491–511.

    PubMed  PubMed Central  CAS  Google Scholar 

  19. Ciurea, M. E., Georgescu, A. M., Purcaru, S. O., Artene, S.–A., Emami, G. H., Boldeanu, M. V., Tache, D. E., and Dricu, A. (2014) Cancer stem cells: biological functions and therapeutically targeting, Int. J. Mol. Sci., 15, 8169–8185.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Di, C., and Zhao, Y. (2015) Multiple drug resistance due to resistance to stem cells and stem cell treatment progress in cancer, Exp. Ther. Med., 9, 289–293.

    Article  PubMed  CAS  Google Scholar 

  21. Green, S. K., Francia, G., Isidoro, C., and Kerbel, R. S. (2004) Antiadhesive antibodies targeting E–cadherin sensi–tize multicellular tumor spheroids to chemotherapy in vitro, Mol. Cancer Ther., 3, 149–159.

    PubMed  CAS  Google Scholar 

  22. Petrova, Y. I., Schecterson, L., and Gumbiner, B. M. (2016) Roles for E–cadherin cell surface regulation in can–cer, Mol. Biol. Cell, 27, 3233–3244.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Chao, Y., Wu, Q., Shepard, C., and Wells, A. (2012) Hepatocyte induced re–expression of E–cadherin in breast and prostate cancer cells increases chemoresistance, Clin. Exp. Metastasis, 29, 39–50.

    Article  PubMed  CAS  Google Scholar 

  24. Wells, A., and Ma, B. (2017) Friend turned foe: E–cadherin perversely protects micrometastases, Transl. Androl. Urol., 6, 338–340.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Farmakovskaya, M., Khromova, N., Rybko, V., Dugina, V., Kopnin, B., and Kopnin, P. (2016) E–cadherin repression increases amount of cancer stem cells in human A549 lung adenocarcinoma and stimulates tumor growth, Cell Cycle, 15, 1084–1092.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Veitonmaki, N., Hansson, M., Zhan, F., Sundberg, A., Lofstedt, T., Ljungars, A., Li, Z.–C., Martinsson–Niskanen, T., Zeng, M., Yang, Y., Danielsson, L., Kovacek, M., Lundqvist, A., Martensson, L., Teige, I., Tricot, G., and Frendeus, B. (2013) A human ICAM–1 antibody iso–lated by a function–first approach has potent macrophage–dependent antimyeloma activity in vivo, Cancer Cell, 23, 502–515.

    Article  PubMed  CAS  Google Scholar 

  27. Hale, M. D., Hayden, J. D., and Grabsch, H. I. (2013) Tumour–microenvironment interactions: role of tumour stroma and proteins produced by cancer–associated fibro–blasts in chemotherapy response, Cell. Oncol., 36, 95–112.

    Article  CAS  Google Scholar 

  28. Klemm, F., and Joyce, J. A. (2015) Microenvironmental regulation of therapeutic response in cancer, Trends Cell Biol., 25, 198–213.

    Article  PubMed  Google Scholar 

  29. Hanahan, D., and Coussens, L. M. (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment, Cancer Cell, 21, 309–322.

    Article  PubMed  CAS  Google Scholar 

  30. Berns, A., and Pandolfi, P. P. (2014) Tumor microenviron–ment revisited, EMBO Rep., 15, 458–459.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Bissell, M. J., and Hines, W. C. (2011) Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression, Nat. Med., 17, 320–329.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Shain, K. H., and Dalton, W. S. (2001) Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR, Mol. Cancer Ther., 1, 69–78.

    PubMed  CAS  Google Scholar 

  33. Paszek, M. J., Zahir, N., Johnson, K. R., Lakins, J. N., Rozenberg, G. I., Gefen, A., Reinhart–King, C. A., Margulies, S. S., Dembo, M., Boettiger, D., Hammer, D. A., and Weaver, V. M. (2005) Tensional homeostasis and the malignant phenotype, Cancer Cell, 8, 241–254.

    Article  PubMed  CAS  Google Scholar 

  34. Marturano–Kruik, A., Villasante, A., Yaeger, K., Ambati, S. R., Chramiec, A., Raimondi, M. T., and Vunjak–Novakovic, G. (2018) Biomechanical regulation of drug sensitivity in an engineered model of human tumor, Biomaterials, 150, 150–161.

    Article  PubMed  CAS  Google Scholar 

  35. Schrader, J., Gordon–Walker, T. T., Aucott, R. L., van Deemter, M., Quaas, A., Walsh, S., Benten, D., Forbes, S. J., Wells, R. G., and Iredale, J. P. (2011) Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells, Hepatology, 53, 1192–1205.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Shin, J.–W., and Mooney, D. J. (2016) Extracellular matrix stiffness causes systematic variations in proliferation and chemosensitivity in myeloid leukemias, Proc. Natl. Acad. Sci. USA, 113, 12126–12131.

    Article  PubMed  CAS  Google Scholar 

  37. Villasante, A., and Vunjak–Novakovic, G. (2015) Tissue–engineered models of human tumors for cancer research, Expert Opin. Drug Discov., 10, 257–268.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Carvalho, M. R., Lima, D., Reis, R. L., Oliveira, J. M., and Correlo, V. M. (2017) Anti–cancer drug validation: the con–tribution of tissue engineered models, Stem Cell Rev. Reports, 13, 347–363.

    Article  CAS  Google Scholar 

  39. Northey, J. J., Przybyla, L., and Weaver, V. M. (2017) Tissue force programs cell fate and tumor aggression, Cancer Discov., 7, 1224–1237.

    Article  PubMed  CAS  Google Scholar 

  40. Bebawy, M., Combes, V., Lee, E., Jaiswal, R., Gong, J., Bonhoure, A., and Grau, G. E. R. (2009) Membrane microparticles mediate transfer of P–glycoprotein to drug sensitive cancer cells, Leukemia, 23, 1643–1649.

    Article  PubMed  CAS  Google Scholar 

  41. Raposo, G., and Stoorvogel, W. (2013) Extracellular vesi–cles: exosomes, microvesicles, and friends, J. Cell Biol., 200, 373–383.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. van der Pol, E., Boing, A. N., Harrison, P., Sturk, A., and Nieuwland, R. (2012) Classification, functions, and clini–cal relevance of extracellular vesicles, Pharmacol. Rev., 64, 676–705.

    Article  PubMed  CAS  Google Scholar 

  43. Zaborowski, M. P., Balaj, L., Breakefield, X. O., and Lai, C. P. (2015) Extracellular vesicles: composition, biological relevance, and methods of study, Bioscience, 65, 783–797.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Chevkina, E. M., Shcherbakov, A. M., and Zhuravskaya, A. Yu. (2015) Exosomes and transfer of epigenetic information in cancer cells, Yspekhi Mol. Onkol., 2, 8–20.

    Google Scholar 

  45. Munson, P., and Shukla, A. (2015) Exosomes: potential in cancer diagnosis and therapy, Medicines, 2, 310–327.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Roseblade, A., Luk, F., Ung, A., and Bebawy, M. (2015) Targeting microparticle biogenesis: a novel approach to the circumvention of cancer multidrug resistance, Curr. Cancer Drug Targets, 15, 205–214.

    Article  PubMed  CAS  Google Scholar 

  47. Pokharel, D., Padula, M. P., Lu, J. F., Tacchi, J. L., Luk, F., Djordjevic, S. P., and Bebawy, M. (2014) Proteome analysis of multidrug–resistant, breast cancer–derived microparticles, J. Extracell. Vesicles, 3, 24384.

    Article  CAS  Google Scholar 

  48. Johnson, P., and Ruffell, B. (2009) CD44 and its role in inflammation and inflammatory diseases, Inflamm. Allergy Drug Targets, 8, 208–220.

    Article  PubMed  CAS  Google Scholar 

  49. Miletti–Gonzalez, K. E., Chen, S., Muthukumaran, N., Saglimbeni, G. N., Wu, X., Yang, J., Apolito, K., Shih, W. J., Hait, W. N., and Rodriguez–Rodriguez, L. (2005) The CD44 receptor interacts with P–glycoprotein to promote cell migration and invasion in cancer, Cancer Res., 65, 6660–6667.

    Article  PubMed  Google Scholar 

  50. Pokharel, D., Padula, M., Lu, J., Jaiswal, R., Djordjevic, S., and Bebawy, M. (2016) The role of CD44 and ERM proteins in expression and functionality of P–glycoprotein in breast cancer cells, Molecules, 21, 290.

    Article  PubMed  CAS  Google Scholar 

  51. Stickeler, E., Fraser, S. D., Honig, A., Chen, A. L., Berget, S. M., and Cooper, T. A. (2001) The RNA binding protein YB–1 binds A/C–rich exon enhancers and stimulates splicing of the CD44 alternative exon v4, EMBO J., 20, 3821–3830.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. To, K., Fotovati, A., Reipas, K. M., Law, J. H., Hu, K., Wang, J., Astanehe, A., Davies, A. H., Lee, L., Stratford, A. L., Raouf, A., Johnson, P., Berquin, I. M., Royer, H.–D., Eaves, C. J., and Dunn, S. E. (2010) Y–box binding protein–1 induces the expression of CD44 and CD49f lead–ing to enhanced self–renewal, mammosphere growth, and drug resistance, Cancer Res., 70, 2840–2851.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  53. Dhillon, J., Astanehe, A., Lee, C., Fotovati, A., Hu, K., and Dunn, S. E. (2010) The expression of activated Y–box binding protein–1 serine 102 mediates trastuzumab resist–ance in breast cancer cells by increasing CD44+ cells, Oncogene, 29, 6294–6300.

    Article  PubMed  CAS  Google Scholar 

  54. Pokharel, D., Roseblade, A., Oenarto, V., Lu, J. F., and Bebawy, M. (2017) Proteins regulating the intercellular transfer and function of P–glycoprotein in multidrug–resist–ant cancer, Ecancermedicalscience, 11, 768.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Stavrovskaya, A. A., and Moiseeva, N. I. (2016) Non–canonic functions of P–glycoprotein transporter, Biol. Membr. (Moscow), 33, 323–334.

    CAS  Google Scholar 

  56. Smyth, M. J., Krasovskis, E., Sutton, V. R., and Johnstone, R. W. (1998) The drug efflux protein, P–glycoprotein, addi–tionally protects drug–resistant tumor cells from multiple forms of caspase–dependent apoptosis, Proc. Natl. Acad. Sci. USA, 95, 7024–7029.

    CAS  Google Scholar 

  57. Johnstone, R. W., Cretney, E., and Smyth, M. J. (1999) P–glycoprotein protects leukemia cells against caspase–dependent, but not caspase–independent, cell death, Blood, 93, 1075–1085.

    PubMed  CAS  Google Scholar 

  58. Bezombes, C., Maestre, N., Laurent, G., Levade, T., Bettaieb, A., and Jaffrezou, J. P. (1998) Restoration of TNF–alpha–induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P–glycoprotein blocker PSC833, FASEB J., 12, 101–109.

    Article  PubMed  CAS  Google Scholar 

  59. Robinson, L. J., Roberts, W. K., Ling, T. T., Lamming, D., Sternberg, S. S., and Roepe, P. D. (1997) Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts, Biochemistry, 36, 11169–11178.

    Article  PubMed  CAS  Google Scholar 

  60. Pallis, M., and Russell, N. (2000) P–glycoprotein plays a drug–efflux–independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modula–tion of a sphingomyelin–ceramide apoptotic pathway, Blood, 95, 2897–2904.

    PubMed  CAS  Google Scholar 

  61. Pallis, M., Turzanski, J., Grundy, M., Seedhouse, C., and Russell, N. (2003) Resistance to spontaneous apoptosis in acute myeloid leukaemia blasts is associated with P–glyco–protein expression and function, but not with the presence of FLT3 internal tandem duplications, Br. J. Haematol., 120, 1009–1016.

    Article  PubMed  CAS  Google Scholar 

  62. Tainton, K. M., Smyth, M. J., Jackson, J. T., Tanner, J. E., Cerruti, L., Jane, S. M., Darcy, P. K., and Johnstone, R. W. (2004) Mutational analysis of P–glycoprotein: suppression of caspase activation in the absence of ATP–dependent drug efflux, Cell Death Differ., 11, 1028–1037.

    Article  PubMed  CAS  Google Scholar 

  63. Souza, P. S., Madigan, J. P., Gillet, J.–P., Kapoor, K., Ambudkar, S. V., Maia, R. C., Gottesman, M. M., and Fung, K. L. (2015) Expression of the multidrug transporter P–glycoprotein is inversely related to that of apoptosis–associated endogenous TRAIL, Exp. Cell Res., 336, 318–328.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  64. Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C. P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., and Smith, C. A. (1995) Identification and characterization of a new member of the TNF family that induces apoptosis, Immunity, 3, 673–682.

    Article  PubMed  CAS  Google Scholar 

  65. Kano, T., Wada, S., Morimoto, K., Kato, Y., and Ogihara, T. (2011) Effect of knockdown of ezrin, radixin, and moesin on P–glycoprotein function in HepG2 cells, J. Pharm. Sci., 100, 5308–5314.

    Article  PubMed  CAS  Google Scholar 

  66. Zhang, L., Xiao, R., Xiong, J., Leng, J., Ehtisham, A., Hu, Y., Ding, Q., Xu, H., Liu, S., Wang, J., Tang, D. G., and Zhang, Q. (2013) Activated ERM protein plays a critical role in drug resistance of MOLT4 cells induced by CCL25, PLoS One, 8, e52384.

    Google Scholar 

  67. Wang, W.–J., Li, Q.–Q., Xu, J.–D., Cao, X.–X., Li, H.–X., Tang, F., Chen, Q., Yang, J.–M., Xu, Z.–D., and Liu, X.–P. (2008) Interaction between CD147 and P–glycoprotein and their regulation by ubiquitination in breast cancer cells, Chemotherapy, 54, 291–301.

    Article  PubMed  CAS  Google Scholar 

  68. Li, Q.–Q., Wang, W.–J., Xu, J.–D., Cao, X.–X., Chen, Q., Yang, J.–M., and Xu, Z.–D. (2007) Involvement of CD147 in regulation of multidrug resistance to P–gp substrate drugs and in vitro invasion in breast cancer cells, Cancer Sci., 98, 1064–1069.

    Article  PubMed  CAS  Google Scholar 

  69. Jodoin, J., Demeule, M., Fenart, L., Cecchelli, R., Farmer, S., Linton, K. J., Higgins, C. F., and Beliveau, R. (2003) P–glycoprotein in blood–brain barrier endothelial cells: interaction and oligomerization with caveolins, J. Neurochem., 87, 1010–1023.

    Article  PubMed  CAS  Google Scholar 

  70. Belanger, M. M., Gaudreau, M., Roussel, E., and Couet, J. (2004) Role of caveolin–1 in etoposide resistance develop–ment in A549 lung cancer cells, Cancer Biol. Ther., 3, 954–959.

    Article  PubMed  CAS  Google Scholar 

  71. Barakat, S., Demeule, M., Pilorget, A., Regina, A., Gingras, D., Baggetto, L. G., and Beliveau, R. (2006) Modulation of P–glycoprotein function by caveolin–1 phos–phorylation, J. Neurochem., 101, 1–8.

    Article  CAS  Google Scholar 

  72. Bhuin, T., and Roy, J. K. (2014) Rab proteins: the key reg–ulators of intracellular vesicle transport, Exp. Cell Res., 328, 1–19.

    Article  PubMed  CAS  Google Scholar 

  73. Liu, M., Aneja, R., Wang, H., Sun, L., Dong, X., Huo, L., Joshi, H., and Zhou, J. (2007) Modulation of multidrug resistance in cancer cells by the E3 ubiquitin ligase seven–in–absentia homologue 1, J. Pathol., 214, 508–514.

    Article  CAS  Google Scholar 

  74. Kim, H.–B., Lee, S.–H., Um, J.–H., Kim, M.–J., Hyun, S.–K., Gong, E.–J., Oh, W. K., Kang, C.–D., and Kim, S.–H. (2015) Sensitization of chemo–resistant human chronic myeloid leukemia stem–like cells to Hsp90 inhibitor by SIRT1 inhibition, Int. J. Biol. Sci., 11, 923–934.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. Xin, Y., Yin, F., Qi, S., Shen, L., Xu, Y., Luo, L., Lan, L., and Yin, Z. (2013) Parthenolide reverses doxorubicin resistance in human lung carcinoma A549 cells by attenu–ating NF–αB activation and HSP70 up–regulation, Toxicol. Lett., 221, 73–82.

    Article  PubMed  CAS  Google Scholar 

  76. Sutoh, I., Kohno, H., Nakashima, Y., Hishikawa, Y., Tabara, H., Tachibana, M., Kubota, H., and Nagasue, N. (2000) Concurrent expressions of metallothionein, glu–tathione S–transferase–pi, and P–glycoprotein in colorectal cancers, Dis. Colon Rectum, 43, 221–232.

    Article  PubMed  CAS  Google Scholar 

  77. Tsuda, H., Hirohashi, S., Shimosato, Y., Hirota, T., Tsugane, S., Yamamoto, H., Miyajima, N., Toyoshima, K., Yamamoto, T., and Yokota, J. (1989) Correlation between long–term survival in breast cancer patients and amplifica–tion of two putative oncogene–coamplification units: hst–1/int–2 and c–erbB–2/ear–1, Cancer Res., 49, 3104–3108.

    PubMed  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Blokhin Medical Research Center of Oncology, Ministry of Health of the Russian Federation, 115478, Moscow, Russia

    A. A. Stavrovskaya & E. Yu. Rybalkina

Authors
  1. A. A. Stavrovskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Yu. Rybalkina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. A. Stavrovskaya.

Additional information

Original Russian Text © A. A. Stavrovskaya, E. Yu. Rybalkina, 2018, published in Biokhimiya, 2018, Vol. 83, No. 7, pp. 963–971.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Stavrovskaya, A.A., Rybalkina, E.Y. Recent Advances in the Studies of Molecular Mechanisms Regulating Multidrug Resistance in Cancer Cells. Biochemistry Moscow 83, 779–786 (2018). https://doi.org/10.1134/S0006297918070015

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S0006297918070015

Keywords

  • multidrug resistance
  • cell–cell interactions
  • epigenetic regulation
  • microvesicles